Further Reductions in Alirocumab Price Needed to Be Considered Cost-Effective
(1/4, Hannah Dellabella, The Cardiology Advisor) reports “To be cost-effective, the price of alirocumab would have to be reduced significantly, according to results published in the Annals of Internal Medicine. The results indicated that the price [of] alirocumab would have to decrease from its original cost of $14,560 to $1974 annually to make use of the drug cost-effective.” Full
Value-Based Oncology Care Delivery Falls Short of Addressing Patients' Psychosocial Needs
(1/4, Ellen Miller-Sonet, Oncology Nursing News) reports “The ongoing dialogue regarding healthcare payment reform that attempts to incentivize high-value care by linking reimbursement to quality rather than quantity has largely ignored the ultimate consumer/buyer—the patient. Yet, in the minds of clinicians, policy makers, and the public at large, patient-centric care and shared decision-making are fundamental mandates in health care delivery. Part of the solution for reconciling these seemingly disparate tensions may well be to consider psychosocial care as an integral part of patient-centered, high-value care. Notably, psychosocial care has been shown to improve patient outcomes and survival, offset medical costs, and reduce unnecessary emergency room use.” Full
Personalising Treatment for Type 2 Diabetes: Why is NICE so Behind?
(1/4, Samuel Seidu and Kamlesh Khunti, The Pharmaceutical Journal) reports “...When guidelines are used uniformly across the population, evidence-based medicine is translated into clinical practice: care is cost-effectively standardised across the healthcare system to facilitate consistent and effective practice, which improves health outcomes for patients…National spending on guideline development is futile if the guidance is ineffective and not adhered to — NICE needs to quickly catch up with the available evidence.” Full
Drug Prices That Matter
(1/3, Wayne Winegarden, Forbes) reports “...[T]he confusion created by the divergent trends between list prices and transactions prices argues that a better drug pricing system is needed. This system would eliminate the opaque discount and rebating practices that define the current system and move toward a more transparent pricing structure. Further, patients should be empowered to become more effective health care consumers and insurers should play a more effective role managing true health care risks.” Full